PT867184E - Utilizacao de tiagabina para o tratamento de desordens do sono - Google Patents

Utilizacao de tiagabina para o tratamento de desordens do sono

Info

Publication number: PT867184E
Authority: PT; Portugal
Prior art keywords: sleep disorders; tiagabine; utilization; treatment; sub
Prior art date: 1995-07-13

Application number

PT98102356T

Other languages

English (en)

Inventor

Marike Lancel

Original Assignee

Max Planck Ges Zur Forderung W

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-13

Filing date

1996-07-10

Publication date

2002-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7766768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT867184(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-07-10 Application filed by Max Planck Ges Zur Forderung W filed Critical Max Planck Ges Zur Forderung W

2002-04-29 Publication of PT867184E publication Critical patent/PT867184E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Thiazole And Isothizaole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PT98102356T 1995-07-13 1996-07-10 Utilizacao de tiagabina para o tratamento de desordens do sono PT867184E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19525598A DE19525598C2 (de)	1995-07-13	1995-07-13	Schlafmittel

Publications (1)

Publication Number	Publication Date
PT867184E true PT867184E (pt)	2002-04-29

Family

ID=7766768

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT96925704T PT840601E (pt)	1995-07-13	1996-07-10	Thip para o tratamento de desordens do sono
PT98102356T PT867184E (pt)	1995-07-13	1996-07-10	Utilizacao de tiagabina para o tratamento de desordens do sono
PT98102355T PT867178E (pt)	1995-07-13	1996-07-10	Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT96925704T PT840601E (pt)	1995-07-13	1996-07-10	Thip para o tratamento de desordens do sono

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT98102355T PT867178E (pt)	1995-07-13	1996-07-10	Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono

Country Status (12)

Country	Link
US (1)	US5929065A (pt)
EP (3)	EP0867178B1 (pt)
JP (3)	JP3754705B2 (pt)
AT (3)	ATE207349T1 (pt)
AU (1)	AU723954B2 (pt)
CA (1)	CA2226582C (pt)
CL (1)	CL2003002785A1 (pt)
DE (4)	DE19525598C2 (pt)
DK (3)	DK0867184T3 (pt)
ES (3)	ES2166111T3 (pt)
PT (3)	PT840601E (pt)
WO (1)	WO1997002813A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5914333A (en) *	1996-07-31	1999-06-22	Novo Nordisk A/S	Treatment of psychotic disorders
DK0991409T3 (da) *	1997-08-01	2002-03-25	Elan Corp Plc	Farmaceutiske tiagabinindeholdende præparater med reguleret frigivelse
IE970588A1 (en)	1997-08-01	2000-08-23	Elan Corp Plc	Controlled release pharmaceutical compositions containing tiagabine
EP1220658A1 (en) *	1999-09-28	2002-07-10	H. Lundbeck A/S	Melt granulated composition and modified release dosage form prepared from said composition
WO2002000209A2 (en) *	2000-06-26	2002-01-03	Warner-Lambert Company	Gabapentin analogues for sleep disorders
SK15542003A3 (sk) *	2001-05-21	2004-05-04	H. Lundbeck A/S	Topením granulovaný výrobok, spôsob jeho výroby, zmes s jeho obsahom v tuhej tvarovanej farmaceutickej jednotkovej dávkovej forme
EP2145620A3 (en)	2003-06-25	2010-03-17	H. Lundbeck A/S	Gaboxadol for treating depression and other affective disorders
AR045540A1 (es)	2003-09-05	2005-11-02	Lundbeck & Co As H	Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) *	2003-09-10	2007-02-08	Mckernan Ruth	Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
PT1691811E (pt) *	2003-12-11	2014-10-30	Sunovion Pharmaceuticals Inc	Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
US20050137222A1 (en) *	2003-12-18	2005-06-23	H. Lundbeck A/S	Treatment of insomnia in human patients
TW200528098A (en) *	2003-12-18	2005-09-01	Lundbeck & Co As H	Treatment of insomnia in human patients
US20050215521A1 (en) *	2003-12-22	2005-09-29	Karim Lalji	Modafinil combination therapy for improving sleep quality
AU2004308962A1 (en) *	2003-12-24	2005-07-14	Sepracor Inc.	Melatonin combination therapy for improving sleep quality
GB0402118D0 (en)	2004-01-30	2004-03-03	Merck Sharp & Dohme	Polymorphic forms of a GABAA agonist
WO2005079851A2 (en) *	2004-02-18	2005-09-01	Sepracor, Inc.	Dopamine-agonist combination therapy with sedatives for improving sleep quality
CA2561883A1 (en) *	2004-04-02	2005-10-13	H. Lundbeck A/S	Treatment of impaired respiratory function with gaboxadol
GB0417558D0 (en) *	2004-08-06	2004-09-08	Merck Sharp & Dohme	Novel combination therapy
EP2292222A1 (en)	2005-01-28	2011-03-09	H. Lundbeck A/S	Polymorphic Forms of a GABAA Agonist
JP5380930B2 (ja) *	2007-07-24	2014-01-08	大正製薬株式会社	睡眠改善剤
JP2017516868A (ja) *	2014-06-06	2017-06-22	オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	持続性抑制を増加させ、二次性不眠症を治療する方法
JP6735284B2 (ja)	2015-03-24	2020-08-05	ハー・ルンドベック・アクチエゼルスカベット	４，５，６，７−テトラヒドロイソオキサゾロ［５，４−ｃ］ピリジン−３−オールの製造
US9682069B2 (en)	2015-07-17	2017-06-20	Ovid Therapeutics Inc	Methods of treating Dravet syndrome
WO2017015049A1 (en)	2015-07-17	2017-01-26	Ovid Therapeutics Inc.	Methods of treating developmental disorders with gaboxadol
KR102518846B1 (ko)	2016-08-11	2023-04-05	오비드 테라퓨틱스 인크.	간질 장애의 치료를 위한 방법 및 조성물
US10071083B2 (en)	2017-02-03	2018-09-11	Ovid Therapeutics Inc	Use of gaboxadol in the treatment of tinnitus
CA3071939A1 (en)	2017-08-04	2019-02-07	Ovid Therapeutics Inc.	Use of gaboxadol in the treatment of diabetes and related conditions
KR20210062662A (ko)	2018-09-20	2021-05-31	오비드 테라퓨틱스 인크.	투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
GB2594616A (en)	2018-11-21	2021-11-03	Certego Therapeutics Inc	Gaboxadol for reducing risk of suicide and rapid relief of depression
EP3894028B1 (en)	2018-12-14	2024-07-31	Raimondo Fazio	Martial arts training device
WO2020131856A1 (en)	2018-12-17	2020-06-25	Ovid Therapeutics Inc.	Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
CN114786669A (zh)	2019-12-18	2022-07-22	奥维德医疗公司	用于1p36缺失综合征的治疗性治疗的加波沙朵
US11597726B2 (en)	2020-05-20	2023-03-07	Certego Therapeutics Inc.	Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
US20240269206A1 (en) *	2021-08-11	2024-08-15	Psyched Wellness Ltd.	Amanita muscaria extracts and compounds and their beneficial and therapeutic use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4362731A (en) *	1980-09-01	1982-12-07	Sandoz Ltd.	Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4786647A (en) *	1986-06-30	1988-11-22	University Of Florida	Method for eliciting anxiolysis
US5167228A (en) *	1987-06-26	1992-12-01	Brigham And Women's Hospital	Assessment and modification of endogenous circadian phase and amplitude
US5192550A (en) *	1990-05-07	1993-03-09	Alza Corporation	Dosage form for treating central nervous system disorders
US5185446A (en) *	1990-09-04	1993-02-09	Neurogen Corporation	Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
DK58291D0 (da) *	1991-04-02	1991-04-02	Novo Nordisk As	Krystalinsk stof og dets fremstilling
US6077839A (en) *	1992-03-19	2000-06-20	Allergan Sales, Inc.	Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists

1995
- 1995-07-13 DE DE19525598A patent/DE19525598C2/de not_active Expired - Fee Related
1996
- 1996-03-01 US US08/609,461 patent/US5929065A/en not_active Expired - Lifetime
- 1996-07-10 DK DK98102356T patent/DK0867184T3/da active
- 1996-07-10 JP JP50463197A patent/JP3754705B2/ja not_active Expired - Fee Related
- 1996-07-10 EP EP98102355A patent/EP0867178B1/en not_active Expired - Lifetime
- 1996-07-10 PT PT96925704T patent/PT840601E/pt unknown
- 1996-07-10 ES ES98102356T patent/ES2166111T3/es not_active Expired - Lifetime
- 1996-07-10 EP EP98102356A patent/EP0867184B1/en not_active Expired - Lifetime
- 1996-07-10 DK DK98102355T patent/DK0867178T3/da active
- 1996-07-10 WO PCT/EP1996/003018 patent/WO1997002813A1/en active IP Right Grant
- 1996-07-10 PT PT98102356T patent/PT867184E/pt unknown
- 1996-07-10 ES ES98102355T patent/ES2166110T3/es not_active Expired - Lifetime
- 1996-07-10 AT AT96925704T patent/ATE207349T1/de not_active IP Right Cessation
- 1996-07-10 AT AT98102356T patent/ATE207356T1/de not_active IP Right Cessation
- 1996-07-10 AT AT98102355T patent/ATE207352T1/de not_active IP Right Cessation
- 1996-07-10 CA CA002226582A patent/CA2226582C/en not_active Expired - Fee Related
- 1996-07-10 DK DK96925704T patent/DK0840601T3/da active
- 1996-07-10 DE DE69616375T patent/DE69616375T2/de not_active Expired - Fee Related
- 1996-07-10 DE DE69616333T patent/DE69616333T2/de not_active Expired - Fee Related
- 1996-07-10 DE DE69616376T patent/DE69616376T2/de not_active Expired - Fee Related
- 1996-07-10 AU AU66137/96A patent/AU723954B2/en not_active Ceased
- 1996-07-10 ES ES96925704T patent/ES2165990T3/es not_active Expired - Lifetime
- 1996-07-10 EP EP96925704A patent/EP0840601B1/en not_active Expired - Lifetime
- 1996-07-10 PT PT98102355T patent/PT867178E/pt unknown
2003
- 2003-12-30 CL CL200302785A patent/CL2003002785A1/es unknown
2004
- 2004-09-02 JP JP2004256133A patent/JP2005047925A/ja active Pending
2008
- 2008-08-25 JP JP2008215117A patent/JP2009057382A/ja active Pending

Also Published As

Publication number	Publication date
JPH11509194A (ja)	1999-08-17
DK0867184T3 (da)	2002-02-18
PT840601E (pt)	2002-04-29
DE19525598A1 (de)	1997-01-16
DE69616333D1 (de)	2001-11-29
CA2226582C (en)	2008-02-19
AU723954B2 (en)	2000-09-07
ATE207352T1 (de)	2001-11-15
ATE207356T1 (de)	2001-11-15
EP0867178B1 (en)	2001-10-24
US5929065A (en)	1999-07-27
JP2009057382A (ja)	2009-03-19
AU6613796A (en)	1997-02-10
EP0840601B1 (en)	2001-10-24
JP3754705B2 (ja)	2006-03-15
ES2165990T3 (es)	2002-04-01
PT867178E (pt)	2002-04-29
DE69616375D1 (de)	2001-11-29
EP0867184B1 (en)	2001-10-24
EP0867178A1 (en)	1998-09-30
DE69616375T2 (de)	2002-07-11
ES2166110T3 (es)	2002-04-01
DE69616376D1 (de)	2001-11-29
EP0840601A1 (en)	1998-05-13
DK0840601T3 (da)	2002-02-18
ATE207349T1 (de)	2001-11-15
DE69616376T2 (de)	2002-06-27
JP2005047925A (ja)	2005-02-24
WO1997002813A1 (en)	1997-01-30
DE19525598C2 (de)	1997-09-25
CA2226582A1 (en)	1997-01-30
DK0867178T3 (da)	2002-02-18
EP0867184A1 (en)	1998-09-30
DE69616333T2 (de)	2002-07-04
CL2003002785A1 (es)	2005-04-08
ES2166111T3 (es)	2002-04-01

Publication	Publication Date	Title
PT867184E (pt)	2002-04-29	Utilizacao de tiagabina para o tratamento de desordens do sono
BR9912501A (pt)	2001-05-02	Tratamento de distúrbios hiperproliferativos
DK0880350T3 (da)	2002-03-25	Behandling af dissemineret sklerose
DE69800859D1 (de)	2001-07-05	Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
EP1056458A4 (en)	2001-06-20	METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN
MA26592A1 (fr)	2004-12-20	Procede et medicament utilisant des composes cycliques, pour le traitement de la bronchopneumopathie chronique obstructive
GB9500024D0 (en)	1995-03-01	Treatment of excessive cell proliferation disorders
BR9708037A (pt)	1999-07-27	Método para o tratamento de abuso de substância
DK0900085T3 (da)	2006-01-30	Behandling af overdreven aggression med olanzapin
EE200100122A (et)	2002-06-17	R-(+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli kasutamine unehäirete raviks
NO984190L (no)	1998-09-11	FremgangsmÕte for behandling av insomnia
ITCT950008V0 (it)	1995-07-03	Guanciale anatomico cervicale per prevenire e trattare i disturbi della c.v. cervicale